Voluntary nationwide recall: Sucralfate (Nostrum – July)

Jul. 2025Pharmacy Updates

Nostrum Laboratories, Inc. is recalling all lots of Sucralfate Tablets USP 1 gram. Sucralfate is used for the prevention and treatment of certain stomach ulcers.

Nostrum Labs filed bankruptcy on Sept. 30, 2024. In connection with that filing, the company has ceased and shut down operations. Nostrum Labs is initiating a voluntary recall of Sucralfate Tablets USP 1 gram, all lots within expiry, as a result of the closures and discontinuation of its quality activities. This recall pertains only to Sucralfate Tablets USP 1 gram manufactured by Nostrum Labs after June 2023. No other Nostrum Labs products are affected by this recall. Using a product that may not meet quality standards means that the company is unable to confirm that the product has the correct identity, strength, quality, and purity characteristics.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA website below. If you have an affected lot of Sucralfate, you should talk to your doctor before stopping the medication.

As of July 11, 2025, there had been no reports of adverse events related to this recall.

To learn more about this recall, you can take one or more of the steps below.

Recent Announcements

Voluntary nationwide recall: True Metrix (Trividia – May)

Trividia Health is recalling all True Metrix Blood Glucose Systems for an issue with the software design of the E-5 Error Code and instructions for the user in the “Messages” section of the Owner’s Booklet/System instructions for use and online labeling and help guides.
May 2026Pharmacy Updates

Community Care Behavioral Health is excited to announce this free upcoming web-based training opportunity:

A growing body of U.S. and international research demonstrates that the rapid legalization and commercialization of gambling—including online casinos and mobile sports betting platforms—are associated with significant and escalating gambling related harm. Although Pennsylvania specific prevalence data remain limited, available evidence is increasingly concerning, with gambling disorder linked to alarmingly high rates of suicide, psychiatric comorbidity, and social and financial harm. Drawing on lessons from the tobacco and opioid crises, this presentation will examine how delayed recognition and regulation can amplify population level harm, underscoring the need for earlier screening, prevention, and policy engagement. Participants will gain practical guidance on identifying patients at elevated risk, implementing evidence informed screening and diagnostic strategies, and applying current treatment approaches across the lifespan.
May 2026Education/Webinars

Bridging Smiles and Systems: Collaborative Care for Children with Chronic Conditions

Please join us for a live, CME-accredited and CEU-accredited webinar on May 13 from noon to 1p.m., that will explore the critical connection between oral health and pediatric chronic conditions such as diabetes, asthma, congenital heart disease, and ADHD.
Apr. 2026Education/Webinars